Myokardia Inc (NASDAQ:MYOK) has been assigned an average rating of “Buy” from the ten research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $54.83.

MYOK has been the subject of several recent analyst reports. Zacks Investment Research downgraded shares of Myokardia from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Credit Suisse Group restated an “outperform” rating and issued a $55.00 target price (up from $45.00) on shares of Myokardia in a research note on Tuesday, September 19th. TheStreet downgraded shares of Myokardia from a “c” rating to a “d+” rating in a research note on Friday, November 3rd. BMO Capital Markets restated an “outperform” rating and issued a $65.00 target price (up from $45.00) on shares of Myokardia in a research note on Monday, August 21st. Finally, J P Morgan Chase & Co initiated coverage on shares of Myokardia in a research note on Tuesday, December 12th. They issued an “overweight” rating and a $54.00 target price for the company.

In other news, Director Kevin P. Starr sold 601,400 shares of Myokardia stock in a transaction on Tuesday, September 26th. The shares were sold at an average price of $43.00, for a total transaction of $25,860,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Rock Ventures Ii L.P. Third sold 201,400 shares of Myokardia stock in a transaction on Monday, September 25th. The stock was sold at an average price of $43.00, for a total transaction of $8,660,200.00. The disclosure for this sale can be found here. Insiders have sold 1,286,713 shares of company stock valued at $55,102,695 over the last quarter. Insiders own 33.40% of the company’s stock.

Several large investors have recently bought and sold shares of MYOK. Wells Fargo & Company MN lifted its stake in shares of Myokardia by 2,151.7% during the third quarter. Wells Fargo & Company MN now owns 417,439 shares of the biotechnology company’s stock worth $17,887,000 after buying an additional 398,900 shares during the period. VHCP Management II LLC acquired a new stake in shares of Myokardia during the third quarter worth $11,355,000. RTW Investments LP acquired a new stake in shares of Myokardia during the third quarter worth $10,882,000. JPMorgan Chase & Co. lifted its stake in shares of Myokardia by 103.5% during the second quarter. JPMorgan Chase & Co. now owns 476,575 shares of the biotechnology company’s stock worth $6,243,000 after buying an additional 242,408 shares during the period. Finally, Fernwood Investment Management LLC lifted its stake in shares of Myokardia by 409.1% during the third quarter. Fernwood Investment Management LLC now owns 246,382 shares of the biotechnology company’s stock worth $10,557,000 after buying an additional 197,989 shares during the period. Institutional investors and hedge funds own 63.61% of the company’s stock.

Shares of Myokardia (NASDAQ MYOK) remained flat at $$38.05 on Friday. 160,677 shares of the company were exchanged, compared to its average volume of 327,135. Myokardia has a 1 year low of $10.55 and a 1 year high of $49.55.

Myokardia (NASDAQ:MYOK) last announced its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.42) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.42). The company had revenue of $5.63 million during the quarter, compared to the consensus estimate of $6.10 million. Myokardia had a negative net margin of 53.49% and a negative return on equity of 14.92%. Myokardia’s revenue was up 58.6% compared to the same quarter last year. During the same period last year, the firm earned ($0.35) earnings per share. research analysts forecast that Myokardia will post -1.62 EPS for the current fiscal year.

WARNING: This story was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/brokerages-set-myokardia-inc-myok-pt-at-54-83/1771971.html.

About Myokardia

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Analyst Recommendations for Myokardia (NASDAQ:MYOK)

Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.